BAM
AMRX icon

Belpointe Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Belpointe Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,197
Closed -$1.66K – 718
2023
Q1 		$1.66K Hold
1,197
– – ﹤0.01% 3360
2022
Q4 		$2.38K Buy
+1,197
New +$2.68K ﹤0.01% 3203

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Belpointe Asset Management's AMRX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2023, closing a stake of 1,197 shares — an estimated $1.66K sold.

Belpointe Asset Management first reported a position in AMRX in Q4 2022 and held it in 2 quarters. The position peaked at $2.38K in Q4 2022. 128 funds tracked by Wall St. Rank hold AMRX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Amneal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,197 Amneal Pharmaceuticals shares in Q2 2023, an estimated $1.66K.
  • Belpointe Asset Management first reported a position in Amneal Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Amneal Pharmaceuticals position peaked at $2.38K in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.